International Journal of Cardiology
Volume 129, Issue 3 , Pages 379-387 , 13 October 2008

Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study

  • Gilles Montalescot

      Affiliations

    • Institut de Cardiologie, Pitié-Salpêtrière Hospital, Paris, France
    • Corresponding Author InformationCorresponding author. Gilles Montalescot, Institut de Cardiologie, Bureau 2-236, Centre Hospitalier Universitaire Pitié-Salpêtrière, 47 Blvd de l'Hôpital, 75013, Paris, France. Tel.: +33 1 42 16 30 06; fax: +33 1 42 16 29 31.
    • ,
  • Zeki Öngen

      Affiliations

    • Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey
    • ,
  • Ramez Guindy

      Affiliations

    • Cairo Special Hospital, Cairo, Egypt
    • ,
  • Amanda Sousa

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil
    • ,
  • Shu-Zheng Lu

      Affiliations

    • Beijing Anzhen Hospital, Beijing, PR China
    • ,
  • Dev Pahlajani

      Affiliations

    • Kirti Manor, Breach Candy Hospital, Mumbai, India
    • ,
  • André Pellois

      Affiliations

    • sanofi-aventis, Paris, France
    • ,
  • Eric Vicaut

      Affiliations

    • Unité de Recherche Clinique, Hôpital Lariboisière, Paris, France
    • ,
  • for the RIVIERA Investigators

Received 26 February 2007 ,Revised 7 June 2007 ,Accepted 7 July 2007.

References 

  1. Malenka DJ, Wennberg DE, Quinton HA, et al. Gender-related changes in the practice and outcomes of percutaneous coronary interventions in Northern New England from 1994 to 1999. J Am Coll Cardiol. 2002;40:2092–2101
  2. Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol. 2001;37:2215–2239
  3. Popma JJ, Ohman EM, Weitz J, Lincoff AM, Harrington RA, Berger P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest. 2001;119(1 suppl):321S–336S
  4. Fox KA, Anderson FA, Dabbous OH, et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart. 2007;93:177–182
  5. Granger CB, Steg PG, Peterson E, et al. Medication performance measures and mortality following acute coronary syndromes. Am J Med. 2005;118:858–865
  6. Van de Werf F, Gore JM, Avezum A, et al. Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study. BMJ. 2005;330:441
  7. Ryan JW, Peterson ED, Chen AY, et al. Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry. Circulation. 2005;112:3049–3057
  8. Hordijk-Trion M, Lenzen M, Wijns W, et al. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J. 2006;27:671–678
  9. Montalescot G, Chevalier B, Dalby MC, et al. Description of modern practices of percutaneous coronary intervention and identification of risk factors for adverse outcome in the French nationwide OPEN registry. Heart. 2005;91:89–90
  10. Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary intervention in the current era compared with 1985–1986: the National Heart, Lung, and Blood Institute Registries. Circulation. 2000;102:2945–2951
  11. Ross MJ, Herrmann HC, Moliterno DJ, et al. Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. J Am Coll Cardiol. 2003;42:981–988
  12. Blankenship JC, Haldis T, Feit F, et al. Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy). Am J Cardiol. 2006;97:1591–1596
  13. Wu C, Hannan EL, Walford G, et al. A risk score to predict in-hospital mortality for percutaneous coronary interventions. J Am Coll Cardiol. 2006;47:654–660
  14. Palmerini T, Marzocchi A, Marrozzini C, et al. Comparison between coronary angioplasty and coronary artery bypass surgery for the treatment of unprotected left main coronary artery stenosis (the Bologna Registry). Am J Cardiol. 2006;98:54–59
  15. Kasanuki H, Honda T, Haze K, et al. A large-scale prospective cohort study on the current status of therapeutic modalities for acute myocardial infarction in Japan: rationale and initial results of the HIJAMI Registry. Am Heart J. 2005;150:411–418
  16. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804–847
  17. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853–863
  18. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006;355:1006–1017
  19. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators,Yusuf S, Mehta SR, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464–1476
  20. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295:1519–1530
  21. Anderson HV, Shaw RE, Brindis RG, et al. A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol. 2002;39:1096–1103
  22. Srinivas VS, Brooks MM, Detre KM, et al. Contemporary percutaneous coronary intervention versus balloon angioplasty for multivessel coronary artery disease: a comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the Bypass Angioplasty Revascularization Investigation (BARI) study. Circulation. 2002;106:1627–1633
  23. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol. 2003;41:20–25
  24. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2420
  25. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–533
  26. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294:1224–1232
  27. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287:3215–3222
  28. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292:89–96
  29. Agostoni P, Biondi-Zoccai GG, de Benedictis ML, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; Systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol. 2004;44:349–356
  30. Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J Invasive Cardiol. 2000;12(Suppl E):E14–E18
  31. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45–54

☆ Grant support: The RIVIERA study is funded by sanofi-aventis, Paris, France.

☆☆ The authors all served on the advisory board of the RIVIERA registry. In addition, Gilles Montalescot has received research grants from sanofi-aventis, Eli Lilly and Guerbet; honoraria from sanofi-aventis, Eli-Lilly, GSK, MSD, The Medicine's Company, and Pfizer, and has been consulted/on advisory boards for sanofi-aventis, Eli-Lilly, GSK, MSD, The Medicine's Company, Schering Plough, and Pfizer; Andre Pellois was an employee of sanofi-aventis; Amanda Sousa had received enoxaparin.

PII: S0167-5273(07)01714-7

doi: 10.1016/j.ijcard.2007.07.127

International Journal of Cardiology
Volume 129, Issue 3 , Pages 379-387 , 13 October 2008

Article Tools

* Image Usage & Resolution